Ionis Pharmaceuticals, Inc.

BMV:IONS * Stock Report

Market Cap: Mex$116.2b

Ionis Pharmaceuticals Management

Management criteria checks 2/4

Ionis Pharmaceuticals' CEO is Brett Monia, appointed in Jan 2020, has a tenure of 4.92 years. total yearly compensation is $12.50M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth MX$123.16M. The average tenure of the management team and the board of directors is 4.9 years and 8.5 years respectively.

Key information

Brett Monia

Chief executive officer

US$12.5m

Total compensation

CEO salary percentage7.7%
CEO tenure4.9yrs
CEO ownership0.1%
Management average tenure4.9yrs
Board average tenure8.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brett Monia's remuneration changed compared to Ionis Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$359m

Jun 30 2024n/an/a

-US$366m

Mar 31 2024n/an/a

-US$385m

Dec 31 2023US$13mUS$961k

-US$366m

Sep 30 2023n/an/a

-US$409m

Jun 30 2023n/an/a

-US$309m

Mar 31 2023n/an/a

-US$329m

Dec 31 2022US$7mUS$825k

-US$270m

Sep 30 2022n/an/a

US$7m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$13mUS$800k

-US$29m

Sep 30 2021n/an/a

-US$608m

Jun 30 2021n/an/a

-US$550m

Mar 31 2021n/an/a

-US$495m

Dec 31 2020US$11mUS$700k

-US$444m

Sep 30 2020n/an/a

US$94m

Jun 30 2020n/an/a

US$145m

Mar 31 2020n/an/a

US$169m

Dec 31 2019US$7mUS$528k

US$281m

Sep 30 2019n/an/a

US$433m

Jun 30 2019n/an/a

US$402m

Mar 31 2019n/an/a

US$366m

Dec 31 2018US$4mUS$508k

US$277m

Sep 30 2018n/an/a

-US$41m

Jun 30 2018n/an/a

-US$38m

Mar 31 2018n/an/a

US$9m

Dec 31 2017US$2mUS$443k

US$19m

Compensation vs Market: Brett's total compensation ($USD12.50M) is above average for companies of similar size in the MX market ($USD2.32M).

Compensation vs Earnings: Brett's compensation has increased whilst the company is unprofitable.

CEO

Brett Monia (63 yo)

4.9yrs

Tenure

US$12,500,023

Compensation

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...

Leadership Team

NamePositionTenureCompensationOwnership
Brett Monia
Founder4.9yrsUS$12.50m0.11%
MX$ 123.2m
Elizabeth Hougen
Executive VP of Finance & CFO11.9yrsUS$2.89m0.059%
MX$ 68.4m
B. Parshall
Director6.9yrsUS$538.04k0.055%
MX$ 64.2m
Richard Geary
Executive VP & Chief Development Officer16.3yrsUS$2.56m0.054%
MX$ 62.4m
Eric Swayze
Executive Vice President of Research4.9yrsUS$2.56m0.021%
MX$ 24.9m
Darren Gonzales
Chief Accounting Officer & Senior VP4.8yrsno datano data
C. Bennett
Executive VP & Chief Scientific Officer4.9yrsUS$958.87k0.050%
MX$ 58.6m
D. Walke
Senior Vice President of Investor Relationsno datano datano data
Patrick O'Neil
Executive VP11.9yrsUS$3.92m0.031%
MX$ 36.0m
Hayley Soffer
Vice President of Corporate Communicationsless than a yearno datano data
Shannon Devers
Senior Vice President of Human Resources4.8yrsno data0.0050%
MX$ 5.8m
Stanley Crooke
Scientific Advisor3.5yrsUS$2.28mno data

4.9yrs

Average Tenure

64.5yo

Average Age

Experienced Management: IONS *'s management team is considered experienced (4.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brett Monia
Founder5.8yrsUS$12.50m0.11%
MX$ 123.2m
B. Parshall
Director24.3yrsUS$538.04k0.055%
MX$ 64.2m
Joan Herman
Independent Director5.5yrsUS$540.04k0.027%
MX$ 30.9m
Joseph Klein
Independent Director19yrsUS$542.04k0.010%
MX$ 12.1m
Joseph Wender
Lead Independent Director30.9yrsUS$598.04k0.084%
MX$ 97.7m
Michael Hayden
Independent Director6.3yrsUS$528.04k0.020%
MX$ 23.7m
Spencer Berthelsen
Independent Director22.6yrsUS$548.04k0.096%
MX$ 111.8m
Joseph Loscalzo
Independent Chairman of the Board10.8yrsUS$568.04k0.020%
MX$ 23.7m
Allene Diaz
Independent Director3.5yrsUS$530.04k0.010%
MX$ 11.6m
Michael Yang
Independent Directorless than a yearUS$363.05kno data

8.5yrs

Average Tenure

70yo

Average Age

Experienced Board: IONS *'s board of directors are considered experienced (8.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 02:53
End of Day Share Price 2024/12/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ionis Pharmaceuticals, Inc. is covered by 46 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
James BirchenoughBarclays